key: cord-0971968-b48fwai5
authors: Olbrich, L.; Castelletti, N.; Schaelte, Y.; Gari, M.; Puetz, P.; Bakuli, A.; Pritsch, M.; Kroidl, I.; Saathoff, E.; Guggenbuehl Noller, J. M.; Fingerle, V.; Le Gleut, R.; Gilberg, L.; Brand, I.; Falk, P.; Markgraf, A.; Deak, F.; Riess, F.; Diefenbach, M.; Eser, T. M.; Weinauer, F.; Martin, S.; Quenzel, E.-M.; Becker, M.; Durner, J.; Girl, P.; Mueller, K.; Radon, K.; Fuchs, C.; Woelfel, R.; Hasenauer, J.; Hoelscher, M.; Wieser, A.
title: A Serology Strategy for Epidemiological Studies Based on the Comparison of the Performance of Seven Different Test Systems - The Representative COVID-19 Cohort Munich
date: 2021-01-16
journal: nan
DOI: 10.1101/2021.01.13.21249735
sha: edba1f5af0d6136b78007e92032b8058554757f5
doc_id: 971968
cord_uid: b48fwai5

Background. Serosurveys are essential to understand SARS-CoV-2 exposure and enable population-level surveillance, but currently available tests need further in-depth evaluation. We aimed to identify testing-strategies by comparing seven seroassays in a population-based cohort. Methods. We analysed 6,658 samples consisting of true-positives (n=193), true-negatives (n=1,091), and specimens of unknown status (n=5,374). For primary testing, we used Euroimmun-Anti-SARS-CoV-2-ELISA-IgA/IgG and Roche-Elecsys-Anti-SARS-CoV-2; and virus-neutralisation, GeneScript(R)cPassTM, VIRAMED-SARS-CoV-2-ViraChip(R), and Mikrogen-recomLine-SARS-CoV-2-IgG, including common-cold CoVs, for confirmatory testing. Statistical modelling generated optimised assay cut-off-thresholds. Findings. Sensitivity of Euroimmun-anti-S1-IgA was 64.8%, specificity 93.3%; for Euroimmun-anti-S1-IgG, sensitivity was 77.2/79.8% (manufacturer's/optimised cut-offs), specificity 98.0/97.8%; Roche-anti-N sensitivity was 85.5/88.6%, specificity 99.8/99.7%. In true-positives, mean and median titres remained stable for at least 90-120 days after RT-PCR-positivity. Of true-positives with positive RT-PCR (<30 days), 6.7% did not mount detectable seroresponses. Virus-neutralisation was 73.8% sensitive, 100.0% specific (1:10 dilution). Neutralisation surrogate tests (GeneScript(R)cPassTM, Mikrogen-recomLine-RBD) were >94.9% sensitive, >98.1% specific. Seasonality had limited effects; cross-reactivity with common-cold CoVs 229E and NL63 in SARS-CoV-2 true-positives was significant. Conclusion. Optimised cut-offs improved test performances of several tests. Non-reactive serology in true-positives was uncommon. For epidemiological purposes, confirmatory testing with virus-neutralisation may be replaced with GeneScript(R)cPassTM or recomLine-RBD. Head-to-head comparisons given here aim to contribute to the refinement of testing-strategies for individual and public health use.

In December 2019, a cluster of atypical pneumonia of unknown origin was described in the region of Wuhan, 26

Hubei province, China. Subsequently, a novel coronavirus was identified as the causative pathogen: SARS-CoV-2 27 (Severe Acute Respiratory Syndrome Coronavirus 2).(1) As the virus spread rapidly across the globe, the Corona 28

Virus Disease 2019 was declared a pandemic on March 12 th , 2020. 29

Direct detection of viral nucleic acids or the virus itself in bodily fluids is considered the reference standard of 30 acute infection; primarily identified through the use of nasopharyngeal swabs or other respiratory probes.(2) 31

Additionally, serodiagnostics are valuable in order firstly to identify past infections, asymptomatic or symptomatic, 32 and secondly to elucidate transmission dynamics within the population; both being highly relevant to inform 33 evidence-based political decision making.(3, 4) 34

Several serological test systems have been introduced since the beginning of the pandemic.(5) Most target one of 35 two specific viral structures: parts of the trimeric CoV spike (S1-2) complex or the nucleocapsid (N) envelope 36 protein. (6) While the receptor binding domain (RBD) of S1 folds out to bind to the angiotensin-converting enzyme 37 2 (ACE2) receptor, the N-protein is involved in viral assembly and replication. (7) lastly, cross-reactivity with other CoVs has been reported, but its effects on the test readouts remain 46 uncertain.(14-16) 47

Here we present the serological testing systems applied within the Representative COVID-19 Cohort Munich 48 (KoCo19), a prospective sero-incidence study initiated in Munich, Germany, in April 2020.(17, 18) Three 49 independent primary tests (Euroimmun Anti-S1-SARS-CoV-2-ELISA-IgA & -IgG and Elecsys Anti-SARS-CoV-2 Roche 50 N pan−Ig) and a number of confirmatory tests (direct viral neutralisation, GeneScript®cPass TM , Mikrogen-51 recomLine-RBD IgG line immunoassay, VIRAMED-SARS-CoV-2-ViraChip® microarray) were assessed in a head-to-52 head cross-comparison. The tests were conducted on samples from (i.) RT-PCR positive individuals (true-positives), 53 (ii.) blood donors from the pre-COVID-19 era (true-negatives), and (iii.) subjects with unknown disease status 54 (unknown). Thus, we were able to generate reliable performance estimates for both primary and confirmatory 55 tests by using true-positive and true-negative individuals from the aforementioned cohorts and to subsequently 56 derive optimised cut-offs for our cohort. 57 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ;

Study design and participants. In total, we included 6,658 samples, derived from a set of SARS-CoV-2 RT-PCR 59 positives ("true-positives", n=193), individuals from historical cohorts, blood donors without any indication of 60 SARS-CoV-2 infection ("true-negatives", n=1,091), and specimen of unknown status (n=5,374); details on the 61 cohort characteristics, including collection-timepoints, can be found in the appendix (p.1; p.4 supplemental table 62

1). 63

The study was approved by the Ethics Commission of the Faculty of Medicine at LMU Munich (20-275-V) and the 64 protocol is available online (www.koco19.de ). 17 65 66 Laboratory Assays. All described analyses were performed using EDTA-plasma samples (appendix pp.1 for further 67 details on assays performed, and p.7 supplemental table 3 for details on platforms and units applied). 68

Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgA/IgG (hereafter called EI-S1-IgG, EI-S1-IgA; Euroimmun, Lübeck, 69

Germany) test kits were used according to the manufacturer's instructions. Measurement values were obtained 70 using the quotient of the optical density measurement provided by the manufacturer's software. We evaluated 71

Elecsys Anti-SARS-CoV-2 Roche anti-N pan-Ig (hereafter called Ro-N-Ig; Roche, Mannheim, Germany) in 72 accordance with the manufacturer's guidelines. Values reported are the Cut-Off-Index (COI) of the individual 73 samples. Operative replicates of the same samples were performed to assess reliability of primary assay 74

For confirmatory testing, we conducted micro-virus neutralisation assays (NT) as described previously,(19) with 76 the exception that confluent cells were incubated instead of adding cells following neutralisation reaction 77 (appendix pp.1). We classified samples with a titre <1:10 as "NT-negative" and samples with a titre ≥1:10 as "NT-78 positive". The dilution steps indicated are <10, 10, 20, 40, and >80. 79 SARS-CoV-2 surrogate virus neutralisation test (GS-cPass; GenScript®, Piscataway, New Jersey, USA) was used to 80 measure binding inhibition, according to the manufacturer's instructions. The inhibition was calculated in 81 percentages, ranging from -30 to 100. 82

For SARS-CoV-2 ViraChip® microarray (VIRAMED Biotech AG, Planegg, Germany; hereafter named VC-N-83

IgA/IgM/IgG; VC-S1-IgA/IgM/IgG; VC-S2-IgA/IgM/IgG) execution followed the manufacturer's instructions. We 84 obtained measurement values by the automated ELISA-processor in arbitrary units. 85

As outlined by the manufacturer, we conducted the recomLine SARS-CoV-2 IgG line immunoassay (MG-S1, MG-N, 86 MG-RBD; Mikrogen, Neuried, Germany), values below the cut-off of 1 were categorized "negative" without 87 quantitative information. Common-cold CoV-2 targets of 229E, NL63, OC43, and HKU1 were included in the 88 aforementioned assay. 89 90 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Statistical Analysis. Prior to analysis, we cleaned and locked the data. For the analyses and visualisation, we used 91 the software R, version 4.0.2. Only one sample per individual was included in the statistical analyses; in case of 92 individuals with multiple blood samples, we only considered the sample with the most complete dataset. For 93 multiple measurements with complete datasets, we only included the first measurement; for operational 94 replicates we used the latest. We subsequently carried out sensitivity and specificity analyses for true-negative 95 and true-positive samples over all the tests performed. 96

We report square roots R of coefficients of determination for association among continuous variables. For paired 97 sample comparisons, we applied Wilcoxon-sign-rank tests, whereas for multiple group comparisons we applied 98

Kruskal-Wallis tests, followed by post-hoc Dunn tests using the Benjamini-Yekutieli adjustment for pairwise 99

Using true-positives and true-negatives, we determined optimised cut-off thresholds and their confidence 101 intervals by a nonparametric bootstrap. In a similar way, we trained random forest and support vector machine 102 classifiers. We calculated estimates for sensitivities, specificities, and overall prediction accuracies for all 103 Role of funding source. The funders had no role in study design, data collection, data analysis, data interpretation, 113 writing or submission for publication of this manuscript. 114 115 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ;

We assessed SARS-CoV-2 antibodies in a total of 6,658 independent samples using EI-S1-IgA (n=6,657), EI-S1-IgG 117 (n=6,658), and Ro-N-Ig (n=6,636) (figure 1, appendix p.4 supplemental table 1). Supplemental table 2 presents an 118 overview of all tests performed (appendix p.5); table 1 outlines sensitivity and specificity of both primary and 119 confirmatory tests by applying both manufacturers' and optimised cut-offs. 120 121 Performance of Primary Tests. When we applied optimised cut-offs to the true-positive and true-negative 122 samples, EI-S1-IgA had a sensitivity of 64.8% and a specificity of 92.6%, while EI-S1-IgG had a sensitivity of 79.8% 123 and a specificity of 97.8% (table 1). The measurement value distribution of the EI-assays is depicted in figure 2A . 124

In the second half of the study period, a decrease in overall IgA-positivity was observed, while overall IgG-positivity 125 remained stable. Subsequent retesting of biobanked samples of the first weeks of sampling with kits of later 126 batches demonstrated overall lower IgA-positivity rates than in the first measurements. This was likely caused by 127 a batch effect, as retesting of samples from the second half of the sampling period did not reproduce these 128 findings; for the first period, it led to changes in classification from positive to negative in the operational replicates 129 (depicted as "positive-negative" in figure 2B and appendix p.8 supplemental figure 1A) . 130

The sensitivity and specificity of Ro-N-Ig with optimised cut-offs were 88.6% and 99.7%, respectively (table 1) For evaluation of primary test concordance, we excluded EI-S1-IgA due to inferior performance in sensitivity and 135 specificity. The concordance between EI-S1-IgG and Ro-N-Ig was 98.5% (6,538/6,636), where 4.0% (264/6,636) of 136 the samples were classified as positive and 94.5% (6,274/6,636) as negative unanimously. Of the remaining 137 samples (1.5%; 98/6,636), 56.1% (55/98) were classified as positive by El-S1-IgG and negative by Ro-N-Ig (figure 138 4A), while the remaining 43.9% (43/98) were negative for EI-S1-IgG and positive for Ro-N-Ig. To clarify their true 139 serostatus, confirmatory testing was performed where possible (appendix p.26 supplemental figure 8). 140

To assess the dependence of result read-out on sampling timepoints, we considered the temporal distribution of 141 baseline titres over the sampling period (appendix pp.11 supplemental figure 2). Here, we considered the mean 142 and median sample values above and below cut-off separately and found them to be comparable over the whole 143 sampling period. Samples from blood donors were available from two distinct sample timepoints (before and after 144 the common cold season). We noticed discrete baseline titre increases in spring without significant changes in 145 overall positivity rate (appendix p.14 supplemental figure 3). 146

To assess the dynamics of the antibody levels in RT-PCR positive subjects, we analysed the measurement values 147 between the RT-PCR test and blood sampling for three time intervals: <30 days, 30-90 days, and >90 days. Across 148 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101/2021.01.13.21249735 doi: medRxiv preprint the whole cohort, we did not observe an initial rise of EI-S1-IgA and EI-S1-IgG but found that EI-S1-IgA decreased 149 at later time points (p=0.02), while the distribution of EI-S1-IgG remained steady (figure 3). For Ro-N-Ig COI we 150 detected an increase in antibody levels (p<0.001), most notably between <30 and 30-90 days (p=0.02). 151 152 Performance of confirmatory tests. A sample subset (n=362; figure 1 ) underwent confirmatory testing. The 153 overall confirmatory test performance is presented in figure 5 and table 1. The sensitivity was 73.8% for direct NT 154

(1:10 dilution), 96.3% for GS-cPass, and 94.9% for MG-RBD. All three tests had a specificity close to 100% (figure 155

NT-titres in our cohort were low -mostly 1:10 -and few had high neutralisation titres of 1:80 or above (figure 157 5A). Measurement values for MG-S1 and MG-RBD were often similar, with few samples showing a reaction against 158 S1 (and N) but not RBD (3.7%; 5/134). For the VC-array, sensitivities of both VC-S1-IgG and VC-N-IgG were 159 improved markedly by optimising cut-offs, with gains of >30% (VC-N-IgG 39.8%/93.5%; VC-S1-IgG 65.8/93.4%; 160 table 1, figure 5 ). Notably, a considerable number of samples (36.0%; 40/111) were reactive against S1 and N but 161 not S2 (figure 5D). 162 The categorical concordance for GS-cPass, MG-RBD, and MG-N with both Ro-N-Ig and EI-S1-IgG was similar (94% 170 or above), while the concordance of NT with both primary tests was lower (74%; figure 7A-H). Concordances were 171 improved by applying the optimised cut-offs, especially for VC-S1-IgG and VC-S2-IgG. 172

To derive an algorithm for an optimised testing-strategy, we also investigated potential gains when applying 173 multiple primary tests. Interestingly, combining different primary tests via machine learning techniques (random 174 forest and support vector machine) barely improved the performance beyond what was achieved by Ro-N-Ig alone 175 (table 1) , neither could we demonstrate an added value of performing more than one confirmatory test. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101/2021.01.13.21249735 doi: medRxiv preprint

We performed head-to-head comparison of seven seroassays for SARS-CoV-2 in a well-defined cohort with 6,658 183 samples. The overwhelming majority of infections could be detected by antibodies even more than three months 184 after infection. In addition, we generated optimised cut-offs which improved sensitivity in primary tests and 185 enhanced the performance of several confirmatory tests. We furthermore showed that surrogate tests, such as 186

GeneScript®cPass TM or RBD line-blot, should be considered instead of the infrastructurally challenging NT in large 187 scale studies, such as vaccine trials or epidemiological surveys. In addition, we observed limited seasonality effects 188 and a significant cross-reactivity with common-cold CoV 229E and NL63 in SARS-CoV-2 true-positive subjects. 189

We calculated diagnostic accuracy indicators for seroassays based on true-positive and true-negative samples and 191 derived optimised cut-offs for the evaluated assays. We subsequently applied these to a set of samples of 192 unknown infection status. (17) As reported previously, there is little diagnostic gain from EI-S1-IgA if EI-S1-IgG is 193 used on the same samples. (4) Our study suggests that Ro-N-Ig performs more reliably than EI-S1-IgA and EI-S1-194

IgG; hence the application of the latter two is of questionable use for low-prevalence settings, considering their 195 lower specificity. 196

For seroprevalence studies it is essential to know how long the measured antibody response remains stable and 197 detectable. There have been different reports of a rapid decline in titre over time. (10, 21) In this analysis, we 198 observed similar declines for EI-S1-IgA titres, which were highest within the first 30 days but dropped significantly 199 thereafter. In contrast, for both EI-S1-IgG and Ro-N-Ig, average titres did not decrease over a period of more than cPass and 94.9% for MG-RBD, using the manufacturer's thresholds. In contrast, we improved the sensitivity for 206 the VC-array markedly by applying optimised cut-offs, with a gain of >50% for VC-N-IgG (39.8%-93.5%) and almost 207 30% for VC-S1-IgG (65.8-93.4%). 208

To generate reliable data for surrogate neutralisation markers (GS-cPass, MG-RBD) feasible for epidemiological 209 purposes, true-positive samples with low neutralising activity are preferable. Our cohort consists mainly of oligo-210 or asymptomatic COVID-19 subjects -NT-titres observed were generally low as expected -suggesting an NT 211 dilution decrease from 1:10 to 1:5 might improve sensitivity in similar settings. As MG-RBD, GS-cPass, and NT 212 performed similarly and correlated well, suggesting an interchangeability of one another, for example for certain 213 epidemiological questions. NT requires complex BSL-3-laboratory infrastructures (virus-culture) which currently 214 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101/2021.01.13.21249735 doi: medRxiv preprint represents a critical bottleneck, while GC-cPass and MG-RBD can be performed under much less stringent safety 215 requirements. While NT is a direct representation of viral neutralisation, GS-cPass assesses the antibody-mediated 216 inhibition of ACE2-interaction with SARS-CoV-2-S1-RBD and is therefore a cell-free neutralisation surrogate 217 marker.(23) Both assays are independent of antibody-subclasses. In contrast, MG-RBD solely detects the RBD-IgG-218 antibody interaction. The discrepant results in our sample set (figure 6D) suggest either a different neutralisation 219 mode than binding to the RBD as used in MG-RBD, or neutralisation due to other subclasses than IgG. 220

The influence of previous or acute infections with common-cold CoV and a resulting cross-reactivity in SARS-CoV-222 2 assays has been discussed previously.(15, 16) Biologically, it is impacted by the target used, wherein whole virus-223 or nucleocapsid proteins are particularly prone to cross-reactivity; this also applies for SARS-CoV-2. (6, 14, 15, 24 ) 224

Comparing true-negative samples from before and after the common cold season, we observed a marginal 225 seasonal increase in the measurement values of EI-S1-IgA, EI-S1-IgG, and Ro-N-Ig (supplemental figure 3) . There 226 was a clear association between SARS-CoV-2 RT-PCR positivity and reactivity against 229E and NL63 N-protein; 227 this suggests that SARS-CoV-2 infected individuals develop a cross-reactivity in the assay against two of the four 228 tested CoV strains. Alternatively, in subjects with previous common cold, this could be explained by a cross-229 stimulation of pre-existing cells specific to the respective common cold coronavirus strain. Similar findings were 230 described recently in a systematic review.(6) 231 232 Using the best-performing primary tests (EI-S1-IgG and Ro-N-Ig), we observed a relevant number of discordantly 233 classified samples (1.5%; 98/6,636; appendix p. 27 supplemental figure 8). Constellations of Ro-N-Ig negative and 234 EI-S1-IgG positive were observed frequently (56.1%; 55/98), with many samples being true-negatives (41.8%; 235 23/55), but none being true-positive (0%; 0/55). The overwhelming majority of those with unknown infection 236 status were negative in NT and GS-cPass (87.5%; 28/32). As the testing principle of EI-S1-IgG is based on S1-237 reactivity, positive virus neutralisation or a neutralisation surrogate can be expected if the reaction is specific, 238

suggesting unspecific cross-reactivity in this group. 239

In contrast, discordant serology with Ro-N-Ig positive and EI-S1-IgG negative was less frequent (43.9%; 43/98), 240 mostly from true-positives >40 days after positive RT-PCR (16.3%; 16/98). This is strongly suggestive of an inability 241 of these individuals to mount a detectable response against S1 during the natural infection. Late or lacking 242 seroconversion has been described previously, mostly in oligo-or asymptomatic subjects. different antibodies against SARS-CoV-2 was 11 days, similar to SARS-CoV-1;(6) however, serological kinetics vary 246 across the severity gradients of symptoms. (6, (9) (10) (11) Additionally, misclassification of subjects might have occurred 247 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 due to RT-PCR-sample mix-up, unspecific reactivity, or contamination in the PCR-test; plausible scenarios in the 248 current pandemic situation where clinical and laboratory infrastructures are overburdened with high sample 249

CoV-2 and therefore a misclassification might not be detected. 251

In our cohort of mostly oligosymptomatic true-positive subjects, 11.4% (22/193) were not detected in the primary 252 serological tests. Of these, 36.4% (8/22) were below 30 days after RT-PCR. A total of 6.0% (7/116) showed no 253 evidence of seroconversion in the group >90 days after RT-PCR. For one subject, the RT-PCR date was unknown. 254

Overall, in our dataset of samples >30 days after positive RT-PCR, a modest 8.1% (13/160) remained negative. 255

In addition to identifying suitable tests dependent upon the approach chosen, applying optimised cut-offs might 257 be a tool to enhance test performance.(4, 29) For EI-S1-IgG, Meyer et al. proposed optimised thresholds for both 258 lower and higher cut-offs.(4) However, a seroprevalence study in Geneva compared both recommended and 259 optimised cut-offs, but did not see any qualitative change.(30) The authors proposed evaluating the 260 manufacturer's cut-off before routine testing, and highlighted the dilemma of securing both rule-in and rule-out 261

properties to mitigate the risk of incorrect classification in a situation with highly-dynamic pre-test probabilities.(4) 262

For both EI-S1-IgG and Ro-N-Ig we demonstrated that sensitivity improved using optimised cut-offs, while 263 specificity remained similar. Even though these changes seem minimal, they might translate into a high number 264 of incorrect diagnoses when testing is performed on a large scale: this is especially pertinent in low-prevalence 265 settings, as a particularly high specificity is crucial to achieve a high positive predictive value. It may also be 266 preferable to have a more sensitive cut-off for a primary test and confirm the positives with a highly-specific 267 secondary test system in low prevalence settings. (17) 268 269 Our study has several of limitations. Firstly, the samples are mostly derived from subjects with mild to no 270 symptoms and therefore conclusions drawn here might best apply to an epidemiological rather than a diagnostic 271 approach. Further evaluation using specimens from severely ill subjects or from high-prevalence settings will need 272 to be conducted and compared to the enclosed results. 273

Secondly, the dataset used to estimate optimised cut-offs and performance of the tests is not an unbiased random 274 sample, as all were sampled in the city of Munich, Germany. It cannot be ruled out that blood donors are generally 275 healthier than the general population. Furthermore, not all confirmatory tests were performed on all samples; 276 only a subset, namely those with positive results in at least one primary test and a dedicated negative/positive 277 cohort, were tested using these systems. Finally, we did not have information on underlying health conditions 278 known to increase the quantity of polyclonal antibodies. 279 280 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ;

In conclusion, our study provides a head-to-head cross-comparison of tests and can be used as a resource to 281 enable the refinement of testing-strategies for individual and public-health use. We also investigated the 282 correlations of the different test systems in-depth, considering confounders such as seasonality and titres against 283 common-cold CoV strains. By combining a diagnostic accuracy approach in a well-defined sample set with true-284 positive as well as true-negative specimens and extrapolating the established findings to samples derived from a 285 population-based seroprevalence cohort, we were able to identify reliable test systems for our Prospective COVID- Helmholtz Centre Munich, Bundeswehr Institute of Microbiology, as well as all medical students involved. We 296 thank Judith Eckstein for outstanding support regarding public relations. We thank the teams from the press 297 offices of LMU, University Hospital of LMU Munich, and of Helmholtz Centre Munich. We thank the KoCo19 298 advisory board members Stefan Endres, Stephanie Jacobs, Bernhard Liebl, Michael Mihatsch, Matthias Tschöp, 299

Manfred Wildner, and Andreas Zapf. We thank Accenture for the development of the KoCo19 web-based survey 300 application. We are grateful to the Statistical Office of the City of Munich, Germany, for providing statistical data 301 on the Munich general population. We thank Helmut Küchenhoff for a critical review of an earlier version of the 302 manuscript and Jared Anderson for English language corrections. We are grateful to the Munich police for their 303 support in the fieldwork and for the Munich Surgical Imaging GmbH, Cisco Systems, and the graphic/photo/IT 304 infrastructure departments at the University Hospital of LMU Munich provided support during video production 305 and online events. For their assistance with our fieldwork, we thank the BMW Group for providing free cars as a 306 part of their campaign "BMW hilft Helfenden." We would also like to thank Mercedes-Benz Munich who supported 307 the project infrastructure with Mercedes-Benz Rent. Lastly, we thank the IT Infrastructure Department of the LMU 308 University Hospital Munich. MG acknowledges the support from the Joachim Herz Foundation through the Add-309 on Fellowship for Interdisciplinary Science. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ;

AW and MH report personal fees and non-financial support from Roche Diagnostics, LO reports non-financial 315 support from Roche Diagnostics. AW, MH and LO report non-financial support from Euroimmun, non-financial 316 support from Viramed, non-financial support from Mikrogen. AW, MH, LO report grants, non-financial support 317 and other from German Center for Infection Research DZIF, grants and non-financial support from Government Euroimmun, Roche, Mikrogen, Viramed provided kits and machines for analyses at discounted rates. 331 332 333 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 16, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Table 1: Manufacturer's and optimised cut-off, sensitivity, specificity and accuracy Evaluation of diagnostic accuracy of primary tests was conducted with samples from true-positives (n=193) and true-negatives (n=1073); subsequently, optimised cutoffs were applied to the KoCo19-cohort (see Methods). * For NT, dilutions starting at 1:10 were used; see Methods. ** The random forest and the support vector machine combine all three primary tests, the accuracy measures thus do not relate to specific cut-offs.

True-positives were defined as subjects with a positive RT-PCR; true-negatives as blood donors from the pre-COVID-19 era. In addition, we included individuals recruited into the Representative COVID-19 Cohort Munich (KoCo19), 100 of which were considered as true-negatives. For each participant, a single sample was used for statistical analysis. Among individuals with longitudinal measurements, the blood sample with the most complete dataset was retained. For similar datasets, the earliest measurement was considered. For operational replicates, the latest measurement was used.

Results of primary tests for true-negatives (blue), true-positives (orange), and individuals with unknown SARS-CoV-2 status (grey). (A) Performance of EI-S1-IgA (left), EI-S1-IgG (centre), and Ro-N-Ig (right). Dotted lines mark the manufacturer's cut-off value (between indeterminate and positive for EI, and between negative and positive in Ro) and dashed lines mark the optimised cut-off value as determined in this study. Orange and blue solid lines represent the percentage of test results for true-positives and true-negatives above (blue) or below (orange) the value on the x-axes, respectively. Orange and blue numbers give the percentage of true-positives and true-negatives, which were correctly detected by the test (without brackets: manufacturers' cut-offs; within brackets: optimised cutoffs). Raw values for EI-S1-IgA show a slightly asymmetric but unimodal distribution for the overall population. The EI-S1-IgG raw values show a bimodal distribution. Ro-N-Ig raw values/COI demonstrate a narrow distribution with the bulk of values in the range COI 0.1 and below, whereas a clearly separated second population above COI 10 was observed. For EI-S1-IgG and Ro-N-Ig, the cut-offs separate the blue and orange subpopulations more reliably than for EI-S1-IgA. (B) Consistency of the primary tests on operational replicates (manufacturer's cut-offs). The changes from positive to negative status in EI-S1-IgA was most likely caused by a batch effect. Reliability of the other primary tests was higher.

Titre values of the 187 true-positives with available data on time between RT-PCR and blood sampling for (A) EI-S1-IgA, (B) EI-S1-IgG, and (C) Ro-N-Ig. The read-outs were categorized according to the time after positive RT-PCR (<30 days, 30-90 days, and >90 days). Plots show the individual read-out (orange dots), a density estimate (orange area), the 25-,50-and 75-percentiles (black box), and the mean (black dot). Counts n refer to the number of observations above/below manufacturer's and optimised cut-off for each of the temporal groups (without brackets: manufacturers' cut-offs; within brackets: optimised cut-offs). Pairwise differences are considered only after adjusting for multiple testing. (A) EI-S1-IgA values were highest on average in the category of <30 days and significantly decline thereafter. (B) EI-S1-IgG values were widespread in the group <30 days, and on average do not decline significantly >90 days. (C) Similarly, Ro-N-Ig does not decline during the study period; however, raw values increase over time.

Results of primary tests compared to ground truth for true-negatives (blue), true-positives (orange), and individuals with unknown SARS-CoV-2 status (grey). The dotted lines represent the manufacturer's cut-offs, the dashed lines the optimised cut-offs defined within this study. (A) Pairwise scatter plots for primary tests: EI-S1-IgA vs. EI-S1-IgG (left; n=6657), and Ro-N-Ig vs. EI-S1-IgG (right; n=6636). Percentages in orange indicate fractions of true-positives in the respective quadrant with respect to all true-positives; blue for true-negatives. Percentages were calculated using the optimised cut-off. EI-S1-IgA classified 65% of true-positives correctly and 7% of the true-negatives as positive. EI-S1-IgG classified 80% of the true-positives correctly and 2% of true-negatives incorrectly. 61% of true-positives were identified by both tests unanimously. Comparing Ro-N-Ig and EI-S1-IgG, 80% of true-positives were concordantly classified as positive by both tests, while 98% of the true-negatives were classified as negative. Correlation of true-positives between Ro-N-Ig and EI-S1-IgG was R=0.79. The fraction of true-negatives falsely classified as positives in Ro-N-Ig was below 1%. (B) Parallel coordinate plot of the primary tests. Magnitude of titres of individual samples across the different assay used were similar. The true-negative samples presented as a group in Ro-N-Ig. Only few samples display as high EI-S1-IgG and low Ro-N-Ig; on the contrary, most samples with low EI-S1-IgA titres, have higher titres in EI-S1-IgG and even higher Ro-N-Ig, presenting separately from the negative population. (C) Concordance of primary tests (based on manufacturer's cut-offs). Numbers of paired samples are indicated above the bars. In the two columns on the left, the unspecific reactivity of EI-S1-IgA is represented in green; the concordance of EI-S1-IgG and Ro-N-Ig was pronounced, with 98 (1.5%) discordant results (right bar). (D) Test results of the primary tests (based on optimised cut-offs). Highest concordance was seen in Ro-N-Ig, lowest in EI-S1-IgA. The proportion of false-negatives in the true-positive cohort was 34.7%, 19.7%, and 11.4%, respectively. Applying optimised (dashed line) and manufacturer's (dotted line) cut-off results in a reduction of false-negatives in EI-S1-IgG and Ro-N-Ig for the optimised cut-off.

Comparison of confirmatory tests for true-negatives (blue), true-positives (orange), and individuals with unknown SARS-CoV-2 status (grey). (A) Association between the categorical endpoint of NT and the continuous results of GS-cPass. The test results were positively related; in cases of identical classification agreement with ground truth was frequent. However, more than 20% of true-positives were missed by NT (1:10 dilution; n=354). (B) Association between the categorical endpoint of NT and the continuous results of MG-RBD. In true-positives with low direct neutralization capacity (NT <10), distinction between negative and positive populations was observed with GS-cPass (n=272), highlighting the limited sensitivity of NT (1:10 dilution). (C) Association between GS-cPass and MG-RBD presented with discordant results in 8% (of true-positives) at intermediate test read-outs. The distribution in higher titre ranges were narrow (n=272). (D) Parallel coordinate plot of the two neutralization surrogate tests and NT. Samples with high/low raw values demonstrated similarly in all three tests, as lines present horizontally. However, a subset of individuals with relatively high GS-cPass values and positive outcome in NT were below the cut-off in the MG-RBD assay.

Clinical features of patients infected with 2019 335 novel coronavirus in Wuhan

A 337 serological assay to detect SARS-CoV-2 seroconversion in humans

Disease severity dictates SARS-CoV-2-339 specific neutralizing antibody responses in COVID-19

Validation of a commercially 342 available SARS-CoV-2 serological immunoassay

A 347 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and 348 association with severity

Serodiagnostics 350 for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review

SARS-CoV-2 infection 353 serology: a useful tool to overcome lockdown?

Clinical and immunological 355 assessment of asymptomatic SARS-CoV-2 infections

Longitudinal evaluation 357 and decline of antibody responses in SARS-CoV-2 infection

Stringent 359 thresholds for SARS-CoV-2 IgG assays result in under-detection of cases reporting loss of taste/smell

Antibody responses to SARS-CoV-2 in 362 patients of novel coronavirus disease 2019

Performance 364 characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Serological assays for emerging coronaviruses: challenges and 367 pitfalls

Targets of T Cell 369 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Cross-reactive antibody 372 responses against SARS-CoV-2 and seasonal common cold coronaviruses

Prevalence and risk factors of infection in the representative COVID-19 cohort 375 Munich

Protocol of a 377 population-based prospective COVID-19 cohort study Munich, Germany (KoCo19)

Results of the 380 first pilot external quality assessment (EQA) scheme for anti-SARS-CoV2-antibody testing. Clinical 381 chemistry and laboratory medicine

The control of the false discovery rate in multiple testing under 383 dependency

Antibody responses to SARS-CoV-385 2 in patients with COVID-19

A SARS-CoV-2 surrogate virus 389 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

SARS-CoV-2-reactive T cells 392 in healthy donors and patients with COVID-19

Dynamics of IgG 394 seroconversion and pathophysiology of COVID-19 infections

Detection of SARS-CoV-2 396 antibodies using commercial assays and seroconversion patterns in hospitalized patients

Intrafamilial Exposure to 399 SARS-CoV-2 Induces Cellular Immune Response without Seroconversion

Severe acute 402 respiratory syndrome coronavirus 2− specific antibody responses in coronavirus disease patients. 403 Emerging infectious diseases

Diagnostic performances and 405 thresholds: the key to harmonization in serological SARS-CoV-2 assays?

Seroprevalence of 408 anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Those authors contributed equally + Those authors contributed equally

Disclaimer: this is a pre-print manuscript and has not been peer-reviewed yet 

Results of confirmatory tests compared to ground truth for true-negatives (blue), true-positives (orange), and individuals with unknown SARS-CoV-2 status (grey). Black dotted and dashed lines represent the manufacturer's and the optimised cut-offs, respectively. Orange/blue numbers indicate percentages of true-positives/-negatives correctly detected by the test.(A,C) Distribution of results of NT and GS-cPass. At 1:10 dilution, NT endpoint was categorical with a specificity of 100% in this cohort; sensitivity was 73.8%. GC-cPass manufacturer's cut-off yielded a specificity of 99.1% and a sensitivity of 96%. Adjustments of the cut-off did not improve the performance of the test systems (shown in parentheses).(B) Distribution of results of the VC-array (left) and the MG-line blot (right). Bar charts below violin plots represent information for the categorical part of the tests. Grey numbers give the percentages of positive samples with unknown SARS-CoV-2 as determined by the manufacturer's and optimised cut-offs. Percentages were calculated over the total number of samples of unknown SARS-CoV-2 status with available test results. In the VC-array, S1-IgG / N-IgG performed best as confirmatory tests with 95.4% / 93.5% sensitivity, and 100% / 91.9% specificity, respectively, applying optimised cut-offs. With manufacturer's cut-offs, sensitivity was 65.7% / 39.8%, respectively. With the optimised cut-off, VC-S2-IgG had a sensitivity of 63.9% and a specificity of 99.1%. Performance of VC-S2-IgA and VC-S2-IgM are presented for reference in supplemental figure 4 (appendix p.17), demonstrating a potential use in diagnostics settings. MG-N, -S1 and -RBD had sensitivities of 94.9% or higher, and specificities of 98.1% or higher, no optimisation of cut-offs could not be optimised here.(D) Parallel coordinate plot of VC-Array and MG. Many subjects do not show S2 reaction although strong reactivity against N and S1 can be detected. Comparing individual subjects in NP, RBD and S1 reaction indicates that several individuals developed strong N and S1 reactions whereas RBD was not bound. General concordance between S1 and RBD was, however, observed.(E) Description of concordance between results comparing each confirmatory test with the ground truth. The colour coding is based on the optimised cut-off.

Comparison of primary with confirmatory tests for true-negatives (blue), true-positives (orange), and individuals with unknown SARS-CoV-2 status (grey).(A) EI-S1-IgG and NT show positive correlation (n=354), although 1% of the true-positives were missed by NT (1:10 dilution).(B, C) Correlation of EI-S1-IgG with GS-cPass (n=361) and MG-RBS (n=272) presented as dose dependent for the double-positive values. Concordance for the truepositive subset was >94%.(D) Association of EI-S1-IgG to MG-N (n=355) presented dose-dependent, but not as markedly.(E-H) Association between Ro-N-Ig and the confirmatory tests (n=362, n=273, n= 354, n=354) did not present as dose-dependent, compared to EI-S1-IgG. Concordance between the tests was >95%; except NT, which presented similar patterns to EI-S1-IgG.We observed a population in the upper left quadrant, (B, C, D), clearly negative in the confirmatory tests.